Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates

Background Liver-expressed antimicrobial peptide 2 (LEAP2) is an endogenous ghrelin-receptor antagonist implicated in metabolic regulation. Evidence in polycystic ovary syndrome (PCOS) is limited. We evaluated circulating LEAP2 according to PCOS status and phenotype and examined its metabolic and hormonal correlates. Methods This single-center, cross-sectional study with prospective recruitment included 64 women with PCOS and 24 controls without PCOS. Fasting serum LEAP2 was measured by enzyme-linked immunosorbent assay. Multivariable linear regression of log-transformed LEAP2 was adjusted for body mass index (BMI) and homeostasis model assessment of insulin resistance (HOMA-IR). Within PCOS, Spearman correlations were evaluated with false discovery rate correction. Results Median LEAP2 was higher in women with PCOS than in controls (0.493 [0.287–0.863] vs. 0.333 [0.227–0.439] ng/mL; p=0.027). After adjustment for BMI and HOMA-IR, PCOS was associated with a 60.5% higher LEAP2 concentration (ratio of geometric means, 1.605; 95% CI, 1.221–2.109; p=0.001). Adjusted LEAP2 was higher in both hyperandrogenic and non-hyperandrogenic PCOS than in controls. No statistically significant differences were detected across PCOS phenotypes, although substantial differences could not be excluded. Triglycerides were the only correlate remaining significant after false discovery rate correction (Spearman ρ=0.372; q=0.040). In a post hoc adjusted model, each triglyceride doubling was associated with a 52.9% higher LEAP2 concentration (ratio of geometric means, 1.529; 95% CI, 1.256–1.862; p<0.001). Conclusion Circulating LEAP2 is elevated in PCOS after adjustment for BMI and HOMA-IR. No significant phenotype differences were detected, although larger studies are needed. Its association with triglycerides suggests a potential link with altered lipid-related metabolic signaling.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-19
DOI
https://doi.org/10.3389/fendo.2026.2004756
Primary Topic
Ovarian function and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates

Sevde Nur Fırat, Işılay Taşkaldıran, Mehmet Şeneş, Alican Bozdaş et al.
Frontiers in Endocrinology
Ovarian function and disorders
article

Circulating LEAP2 in women with polycystic ovary syndrome: a cross-sectional study of androgenic phenotypes and metabolic correlates

Sevde Nur Fırat, Işılay Taşkaldıran, Mehmet Şeneş, Alican Bozdaş, Zeynep Bağlan Atalay, Özge Özbaykal
article en

Abstract

Background Liver-expressed antimicrobial peptide 2 (LEAP2) is an endogenous ghrelin-receptor antagonist implicated in metabolic regulation. Evidence in polycystic ovary syndrome (PCOS) is limited. We evaluated circulating LEAP2 according to PCOS status and phenotype and examined its metabolic and hormonal correlates. Methods This single-center, cross-sectional study with prospective recruitment included 64 women with PCOS and 24 controls without PCOS. Fasting serum LEAP2 was measured by enzyme-linked immunosorbent assay. Multivariable linear regression of log-transformed LEAP2 was adjusted for body mass index (BMI) and homeostasis model assessment of insulin resistance (HOMA-IR). Within PCOS, Spearman correlations were evaluated with false discovery rate correction. Results Median LEAP2 was higher in women with PCOS than in controls (0.493 [0.287–0.863] vs. 0.333 [0.227–0.439] ng/mL; p=0.027). After adjustment for BMI and HOMA-IR, PCOS was associated with a 60.5% higher LEAP2 concentration (ratio of geometric means, 1.605; 95% CI, 1.221–2.109; p=0.001). Adjusted LEAP2 was higher in both hyperandrogenic and non-hyperandrogenic PCOS than in controls. No statistically significant differences were detected across PCOS phenotypes, although substantial differences could not be excluded. Triglycerides were the only correlate remaining significant after false discovery rate correction (Spearman ρ=0.372; q=0.040). In a post hoc adjusted model, each triglyceride doubling was associated with a 52.9% higher LEAP2 concentration (ratio of geometric means, 1.529; 95% CI, 1.256–1.862; p<0.001). Conclusion Circulating LEAP2 is elevated in PCOS after adjustment for BMI and HOMA-IR. No significant phenotype differences were detected, although larger studies are needed. Its association with triglycerides suggests a potential link with altered lipid-related metabolic signaling.

Frontiers in EndocrinologyVol. 17
Ministry of Health (TR), University of Health Science (KH), Sağlık Bilimleri Üniversitesi (TR), Ankara Eğitim ve Araştırma Hastanesi (TR), University of Health Sciences Antigua (AG)
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon